Evidence from a meta-analysis for the prognostic and clinicopathological importance of DKC1 in malignancies.
暂无分享,去创建一个
Bin Zhou | Q. Zhang | Xiaohan Liu | Z. Zou
[1] Rong Li,et al. Gene signature to predict prognostic survival of hepatocellular carcinoma , 2022, Open medicine.
[2] Gong Chen,et al. Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer Cells , 2021, Advanced science.
[3] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[4] Zhe Qiao,et al. LncRNA PCAT1 Interacts with DKC1 to Regulate Proliferation, Invasion and Apoptosis in NSCLC Cells via the VEGF/AKT/Bcl2/Caspase9 Pathway , 2021, Cell transplantation.
[5] G. Saretzki,et al. Aberrant Dyskerin Expression Is Related to Proliferation and Poor Survival in Endometrial Cancer , 2021, Cancers.
[6] Chunjie Sheng,et al. Inhibition of DKC1 induces telomere-related senescence and apoptosis in lung adenocarcinoma , 2020, Journal of translational medicine.
[7] A. Green,et al. The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer , 2020, British Journal of Cancer.
[8] A. Tewari,et al. Pseudouridine as a novel biomarker in prostate cancer. , 2020, Urologic oncology.
[9] Yong Duan,et al. LncRNA MEG3 inhibits non-small cell lung cancer via interaction with DKC1 protein , 2020, Oncology letters.
[10] P. Hou,et al. DKC1 enhances angiogenesis by promoting HIF-1α transcription and facilitates metastasis in colorectal cancer , 2019, British Journal of Cancer.
[11] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.
[12] G. Brandi,et al. Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: correlations with cholangiocarcinoma aggressiveness , 2015, Histopathology.
[13] Hong Wang,et al. Unraveling secrets of telomeres: one molecule at a time. , 2014, DNA repair.
[14] L. Montanaro,et al. Inhibition of Human Dyskerin as a New Approach to Target Ribosome Biogenesis , 2014, PloS one.
[15] A. Jemal,et al. Cancer treatment and survivorship statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[16] A. Muñoz-Barrutia,et al. Multiscale in situ analysis of the role of dyskerin in lung cancer cells. , 2013, Integrative biology : quantitative biosciences from nano to macro.
[17] G. Zamolo,et al. Modulating telomerase activity in tumor patients by targeting dyskerin binding site for hTR. , 2012, Medical hypotheses.
[18] Hui Liu,et al. Dyskerin Overexpression in Human Hepatocellular Carcinoma Is Associated with Advanced Clinical Stage and Poor Patient Prognosis , 2012, PloS one.
[19] A. Bertuch,et al. Dyskeratosis congenita as a disorder of telomere maintenance. , 2012, Mutation research.
[20] L. Montanaro. Dyskerin and cancer: more than telomerase. The defect in mRNA translation helps in explaining how a proliferative defect leads to cancer , 2010, The Journal of pathology.
[21] A. Stang. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses , 2010, European Journal of Epidemiology.
[22] David B. Wilson,et al. Dyskeratosis congenita , 2010, FEBS letters.
[23] R. DePinho,et al. Telomeres and telomerase in cancer. , 2010, Carcinogenesis.
[24] R Engers,et al. DKC1 overexpression associated with prostate cancer progression , 2009, British Journal of Cancer.
[25] I. Dokal,et al. Advances in the understanding of dyskeratosis congenita , 2009, British journal of haematology.
[26] L. Montanaro,et al. Nucleolus, ribosomes, and cancer. , 2008, The American journal of pathology.
[27] M. Sydes,et al. Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.
[28] N. Bache,et al. Protein Composition of Catalytically Active Human Telomerase from Immortal Cells , 2007, Science.
[29] J. Clohessy,et al. Dyskerin expression influences the level of ribosomal RNA pseudo‐uridylation and telomerase RNA component in human breast cancer , 2006, The Journal of pathology.
[30] W. Park,et al. Absence of DKC1 exon 3 mutation in common human cancers. , 2006, Acta oncologica.
[31] N. Carter,et al. A DNA damage checkpoint response in telomere-initiated senescence , 2003, Nature.
[32] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[33] A. Cheng,et al. Differential regulation of telomerase activity by six telomerase subunits. , 2002, European journal of biochemistry.
[34] T. Vulliamy,et al. Dyskeratosis Congenita (DC) Registry: identification of new features of DC , 1998, British journal of haematology.
[35] S. Klauck,et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions , 1998, Nature Genetics.
[36] G. Smith,et al. Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.
[37] T. Vulliamy,et al. Fine mapping of the dyskeratosis congenita locus in Xq28. , 1996, Journal of medical genetics.
[38] J. Shay,et al. The reactivation of telomerase activity in cancer progression. , 1996, Trends in genetics : TIG.
[39] C B Harley,et al. Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.
[40] C. Begg,et al. Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.
[41] J. Steitz,et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. , 1992, The EMBO journal.
[42] H. Cooke,et al. In vivo loss of telomeric repeats with age in humans. , 1991, Mutation research.
[43] Robin C. Allshire,et al. Telomere reduction in human colorectal carcinoma and with ageing , 1990, Nature.
[44] C. Harley,et al. Telomeres shorten during ageing of human fibroblasts , 1990, Nature.
[45] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.